Enterprise Financial Services Corp Decreases Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Enterprise Financial Services Corp lowered its stake in Bristol-Myers Squibb (NYSE:BMYGet Rating) by 57.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,711 shares of the biopharmaceutical company’s stock after selling 18,763 shares during the period. Enterprise Financial Services Corp’s holdings in Bristol-Myers Squibb were worth $855,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Two Sigma Advisers LP increased its holdings in shares of Bristol-Myers Squibb by 709.5% in the third quarter. Two Sigma Advisers LP now owns 6,603,299 shares of the biopharmaceutical company’s stock worth $390,717,000 after buying an additional 5,787,600 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in Bristol-Myers Squibb by 377.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 6,034,622 shares of the biopharmaceutical company’s stock valued at $357,069,000 after purchasing an additional 4,769,885 shares during the period. Primecap Management Co. CA increased its holdings in Bristol-Myers Squibb by 16.9% during the 4th quarter. Primecap Management Co. CA now owns 22,114,455 shares of the biopharmaceutical company’s stock valued at $1,378,836,000 after purchasing an additional 3,195,680 shares during the period. Nordea Investment Management AB increased its holdings in Bristol-Myers Squibb by 20.8% during the 4th quarter. Nordea Investment Management AB now owns 18,130,455 shares of the biopharmaceutical company’s stock valued at $1,136,598,000 after purchasing an additional 3,124,811 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new position in Bristol-Myers Squibb during the 4th quarter valued at about $150,857,000. Hedge funds and other institutional investors own 73.07% of the company’s stock.

NYSE BMY traded up $0.20 during mid-day trading on Wednesday, reaching $77.33. The stock had a trading volume of 294,167 shares, compared to its average volume of 15,010,080. Bristol-Myers Squibb has a 1 year low of $53.22 and a 1 year high of $78.46. The stock has a market cap of $164.64 billion, a PE ratio of 27.35, a price-to-earnings-growth ratio of 1.61 and a beta of 0.49. The company has a fifty day moving average price of $75.28 and a 200 day moving average price of $67.32. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.32 and a quick ratio of 1.23.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last announced its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported $1.96 earnings per share for the quarter, topping analysts’ consensus estimates of $1.92 by $0.04. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The company had revenue of $11.65 billion during the quarter, compared to analyst estimates of $11.34 billion. During the same period in the previous year, the business earned $1.74 EPS. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. As a group, equities research analysts expect that Bristol-Myers Squibb will post 7.57 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Monday, May 2nd. Shareholders of record on Friday, April 1st were paid a dividend of $0.54 per share. The ex-dividend date of this dividend was Thursday, March 31st. This represents a $2.16 dividend on an annualized basis and a yield of 2.79%. Bristol-Myers Squibb’s dividend payout ratio is presently 76.60%.

A number of research analysts recently issued reports on the company. StockNews.com assumed coverage on Bristol-Myers Squibb in a report on Thursday, March 31st. They set a “strong-buy” rating on the stock. Morgan Stanley cut their price objective on Bristol-Myers Squibb from $66.00 to $64.00 and set an “underweight” rating on the stock in a research report on Wednesday, April 6th. Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $65.00 to $70.00 and gave the company an “equal weight” rating in a research report on Tuesday, May 17th. Barclays lifted their price objective on Bristol-Myers Squibb from $66.00 to $68.00 in a research report on Monday, May 2nd. Finally, Truist Financial lifted their price objective on Bristol-Myers Squibb from $76.00 to $81.00 in a research report on Monday, May 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $71.89.

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 30,000 shares of the business’s stock in a transaction on Thursday, February 24th. The shares were sold at an average price of $67.00, for a total transaction of $2,010,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Karen Murphy Santiago sold 6,577 shares of the business’s stock in a transaction on Monday, March 14th. The shares were sold at an average price of $69.19, for a total transaction of $455,062.63. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 165,668 shares of company stock valued at $11,459,888. Company insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb (Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

See Also

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYGet Rating).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.